Galmed Pharma (GLMD) Misses Q4 EPS by 5c

Galmed Pharma (NASDAQ: GLMD) reported Q4 EPS of ($0.39), $0.05 worse than the analyst estimate of ($0.34).

For earnings history and earnings-related data on Galmed Pharma (GLMD) click here.

You May Also Be Interested In

• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
• Argus starts SpaceX at Hold, sees record IPO as a multi-year re-rating challenge
• Apple’s big price hike seen as "an unprecedented push to protect margins"